ABSTRACT
BACKGROUND: Duodenal stump fistula (DSF) is a severe complication of gastrectomy. Although nonsurgical therapy is preferred, surgery is still mandatory in one third of DSF patients. The aim of this article is to analyze the surgical management of DSF and factors related to its outcome. METHODS: We performed a retrospective multicenter study using data from January 1990 to November 2011 in 16 Italian surgery centers. We collected 8,268 elective gastrectomies for malignancies, 7,987 by the laparotomic and 281 by the laparoscopic approach. Two hundred five patients developed a DSF, 75 of whom underwent surgery for DSF. We analyzed mortality and DSF healing time as well as the impact of clinical, oncological, and surgical characteristics. RESULTS: The laparoscopic approach increased the risk of DSF development (odds ratio 5.6, 95% confidence interval 2.7-10.6, P < 0.001). The indication for first DSF surgery was intra-abdominal sepsis; the failure rate was over 30%, associated with the appearance of fistulas of neighboring organs, bleeding, and the need for reoperations. The mortality rate was 28% and was related to the presence of vascular disease (P = 0.04), more than one reoperation (P = 0.05), sepsis (P < 0.001), and renal failure (P < 0.001). Fifty-four patients recovered after a median of 39 days (interquartile range 22-68 days); the need to perform more reoperations (P < 0.01) and the presence of an abdominal abscess (P < 0.01) led to an increase in healing time. CONCLUSIONS: Surgery for DSF has a poor prognosis. Our data will help to identify patients at risk of death, but unfortunately could not establish the best surgical procedure applicable to all cases of DSF.
Subject(s)
Duodenal Diseases/surgery , Gastrectomy/adverse effects , Intestinal Fistula/surgery , Postoperative Complications/surgery , Stomach Neoplasms/surgery , Aged , Duodenal Diseases/mortality , Elective Surgical Procedures/adverse effects , Female , Gastrectomy/methods , Humans , Intestinal Fistula/mortality , Italy , Laparoscopy/methods , Laparotomy/methods , Male , Middle Aged , Postoperative Complications/etiology , Prognosis , Retrospective Studies , Stomach Neoplasms/pathology , Treatment OutcomeABSTRACT
BACKGROUND: Helicobacter pylori infection may increase the risk of both histotypes of gastric carcinoma (GC): intestinal (IGC) and diffuse (DGC). Polymorphism of the main H. pylori virulence factors, cagA and vacA, could have a different impact on the histological variety of GC. METHODS: Two hundred and twenty-six H. pylori colonies were examined from 28 GC patients: 15 with IGC and 13 with DGC. DNA was extracted from bacteria and a PCR was performed using primers specific for cagA, the 3' cagA variable region and s and m regions of vacA. RESULTS: There were 214 cagA+ strains and 55.61% of them were isolated from IGC cases; there were 12 cagA- colonies and they were all isolated from DGC (P<0.001). Most patients were infected by strains with more than one cagA structural type. No strains with a particular cagA type were found to be significantly more frequent in either histological variety of GC. A percentage of 43.90 of strains with vacA subtype s1/m1 were isolated from IGC, whereas 80.95% of vacA subtype s1/m2 strains were isolated from DGC cases (P<0.001). CONCLUSION: Polymorphism of the main virulence genes of H. pylori may play different roles in the pathogenesis of IGC and DGC.
Subject(s)
Antigens, Bacterial/genetics , Bacterial Proteins/genetics , Carcinoma/microbiology , Carcinoma/pathology , DNA, Bacterial/genetics , Helicobacter Infections/microbiology , Helicobacter pylori/genetics , Polymorphism, Genetic , Stomach Neoplasms/microbiology , Stomach Neoplasms/pathology , Helicobacter Infections/complications , Helicobacter Infections/diagnosis , Helicobacter pylori/isolation & purification , Helicobacter pylori/pathogenicity , Humans , Phenotype , Polymerase Chain Reaction , Risk Factors , Virulence/geneticsSubject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Chemotherapy, Adjuvant/methods , Colorectal Neoplasms/therapy , Digestive System Surgical Procedures/methods , Hyperthermic Intraperitoneal Chemotherapy/methods , Peritoneal Neoplasms/prevention & control , Acute Kidney Injury/epidemiology , Anastomotic Leak/epidemiology , Cisplatin/administration & dosage , Colorectal Neoplasms/pathology , Humans , Mitomycin/administration & dosage , Oxaliplatin/administration & dosage , Pancreatitis/epidemiology , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/secondary , Postoperative Complications/epidemiologyABSTRACT
BACKGROUND: Duodenal fistula (DF) after gastrectomy continues to be a life-threatening problem. We performed a retrospective multicenter study analyzing the characteristics of DF after elective gastrectomy for malignant disease. METHODS: Three thousand seven hundred eighty-five patients who had undergone gastrectomy with duodenal stump in 11 Italian surgical units were analyzed. RESULTS: Sixty-eight DFs occurred, with a median frequency of 1.6% and a mortality rate of 16%. Complications were mainly septic but fistulas or bleeding of surrounding organs accounted for about 30%. Reoperation was performed in 40% of patients. We observed a correlation between mortality and age (hazard ratio 1.09; 95% CI 1.00-1.20) and serum albumin (hazard ratio 0.90; 95% CI 0.83-0.99). The appearance of further complications was associated with reoperation (P < 0.001) and death (P = 0.054), while the preservation of oral feeding was related to DF healing (P < 0.001). CONCLUSIONS: This paper represents the largest series ever published on DF and shows that its features have changed in the last 20 years. DF alone no longer leads to death and some complications observed in the past have disappeared, while new ones are emerging. Nowadays, medical therapy is preferred and surgery is indicated only in cases of abdominal sepsis or bleeding.
Subject(s)
Duodenal Diseases/etiology , Gastrectomy/adverse effects , Intestinal Fistula/etiology , Stomach Neoplasms/surgery , Anastomosis, Surgical , Chi-Square Distribution , Duodenal Diseases/epidemiology , Duodenal Diseases/surgery , Elective Surgical Procedures/adverse effects , Elective Surgical Procedures/methods , Female , Follow-Up Studies , Gastrectomy/methods , Humans , Incidence , Intestinal Fistula/epidemiology , Intestinal Fistula/surgery , Italy , Kaplan-Meier Estimate , Male , Postoperative Complications/diagnosis , Postoperative Complications/epidemiology , Proportional Hazards Models , Reoperation , Retrospective Studies , Risk Assessment , Statistics, Nonparametric , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology , Survival Analysis , Treatment OutcomeABSTRACT
BACKGROUND: The incidence of gallstones and gallbladder sludge is known to be higher in patients after gastrectomy than in general population. This higher incidence is probably related to surgical dissection of the vagus nerve branches and the anatomical gastrointestinal reconstruction. Therefore, some surgeons perform routine concomitant cholecystectomy during standard surgery for gastric malignancies. However, not all the patients who are diagnosed to have cholelithiasis after gastric cancer surgery will develop symptoms or require additional surgical treatments and a standard laparoscopic cholecystectomy is feasible even in those patients who underwent previous gastric surgery. At the present, no randomized study has been published and the decision of gallbladder management is left to each surgeon preference. DESIGN: The study is a randomized controlled investigation. The study will be performed in the General and Oncologic Surgery, Department of Oncology-Azienda Ospedaliero-Universitaria Careggi-Florence-Italy, a large teaching institution, with the participation of all surgeons who accept to be involved in, together with other Italian Surgical Centers, on behalf of the GIRCG (Italian Research Group for Gastric Cancer).The patients will be randomized into two groups: in the first group the patient will be submitted to prophylactic cholecystectomy during standard surgery for curable gastric cancer (subtotal or total gastrectomy), while in the second group he/she will be submitted to standard gastric surgery only. TRIAL REGISTRATION: ClinicalTrials.gov ID. NCT00757640.